Ambar Protein Industries Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 14, 2025, 10:12 pm

Quick Insight

Ambar Protein Industries Ltd, operating in the Edible Oils & Solvent Extraction industry, currently has a share price of 278 with a market capitalization of 160 Cr. The company's P/E ratio stands at 16.6, indicating a reasonable valuation, while boasting a robust ROE of 32.3% and a commendable ROCE of 27.5%. With a healthy OPM of 2.97% and a net profit of 10 Cr, Ambar Protein Industries has demonstrated efficient operational management. The company's strong promoter holding of 70.99% instills confidence, although the absence of significant FII and DII ownership may be a point for consideration. Overall, with solid financial metrics and a stable shareholder base, Ambar Protein Industries appears well-positioned for sustained growth in the Edible Oils & Solvent Extraction sector.

Competitors of Ambar Protein Industries Ltd

All Competitor Stocks of Ambar Protein Industries Ltd

Quarterly Result

Last Updated: July 16, 2025, 2:56 pm

Below is a detailed analysis of the quarterly data for Ambar Protein Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 127.81 Cr.. The value appears strong and on an upward trend. It has increased from 111.82 Cr. (Dec 2024) to 127.81 Cr., marking an increase of 15.99 Cr..
• For Expenses, as of Mar 2025, the value is 124.02 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 107.00 Cr. (Dec 2024) to 124.02 Cr., marking an increase of 17.02 Cr..
• For Operating Profit, as of Mar 2025, the value is 3.79 Cr.. The value appears to be declining and may need further review. It has decreased from 4.82 Cr. (Dec 2024) to 3.79 Cr., marking a decrease of 1.03 Cr..
• For OPM %, as of Mar 2025, the value is 2.97%. The value appears to be declining and may need further review. It has decreased from 4.31% (Dec 2024) to 2.97%, marking a decrease of 1.34%.
• For Other Income, as of Mar 2025, the value is 0.20 Cr.. The value appears strong and on an upward trend. It has increased from 0.19 Cr. (Dec 2024) to 0.20 Cr., marking an increase of 0.01 Cr..
• For Interest, as of Mar 2025, the value is 0.58 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.57 Cr. (Dec 2024) to 0.58 Cr., marking an increase of 0.01 Cr..
• For Depreciation, as of Mar 2025, the value is 0.21 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.46 Cr. (Dec 2024) to 0.21 Cr., marking a decrease of 0.25 Cr..
• For Profit before tax, as of Mar 2025, the value is 3.20 Cr.. The value appears to be declining and may need further review. It has decreased from 3.98 Cr. (Dec 2024) to 3.20 Cr., marking a decrease of 0.78 Cr..
• For Tax %, as of Mar 2025, the value is 22.19%. The value appears to be improving (decreasing) as expected. It has decreased from 29.15% (Dec 2024) to 22.19%, marking a decrease of 6.96%.
• For Net Profit, as of Mar 2025, the value is 2.48 Cr.. The value appears to be declining and may need further review. It has decreased from 2.82 Cr. (Dec 2024) to 2.48 Cr., marking a decrease of 0.34 Cr..
• For EPS in Rs, as of Mar 2025, the value is 4.31. The value appears to be declining and may need further review. It has decreased from 4.90 (Dec 2024) to 4.31, marking a decrease of 0.59.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:02 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:55 pm

Below is a detailed analysis of the balance sheet data for Ambar Protein Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 6.00 Cr..
• For Reserves, as of Mar 2025, the value is 29.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Mar 2024) to 29.00 Cr., marking an increase of 10.00 Cr..
• For Borrowings, as of Mar 2025, the value is 26.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 26.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 10.00 Cr.. The value appears to be improving (decreasing). It has decreased from 11.00 Cr. (Mar 2024) to 10.00 Cr., marking a decrease of 1.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 70.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 61.00 Cr. (Mar 2024) to 70.00 Cr., marking an increase of 9.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2024) to 18.00 Cr., marking a decrease of 1.00 Cr..
• For CWIP, as of Mar 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 51.00 Cr.. The value appears strong and on an upward trend. It has increased from 42.00 Cr. (Mar 2024) to 51.00 Cr., marking an increase of 9.00 Cr..
• For Total Assets, as of Mar 2025, the value is 70.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Mar 2024) to 70.00 Cr., marking an increase of 9.00 Cr..

Notably, the Reserves (29.00 Cr.) exceed the Borrowings (26.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Ambar Protein Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 16.79. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.79, marking an increase of 11.32.
• For Diluted EPS (Rs.), as of Mar 25, the value is 16.79. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.79, marking an increase of 11.32.
• For Cash EPS (Rs.), as of Mar 25, the value is 19.06. This value is within the healthy range. It has increased from 7.75 (Mar 24) to 19.06, marking an increase of 11.31.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.39. It has increased from 43.60 (Mar 24) to 60.39, marking an increase of 16.79.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.39. It has increased from 43.60 (Mar 24) to 60.39, marking an increase of 16.79.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 733.26. It has increased from 586.19 (Mar 24) to 733.26, marking an increase of 147.07.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 28.89. This value is within the healthy range. It has increased from 13.72 (Mar 24) to 28.89, marking an increase of 15.17.
• For PBIT / Share (Rs.), as of Mar 25, the value is 26.61. This value is within the healthy range. It has increased from 11.43 (Mar 24) to 26.61, marking an increase of 15.18.
• For PBT / Share (Rs.), as of Mar 25, the value is 22.66. This value is within the healthy range. It has increased from 7.16 (Mar 24) to 22.66, marking an increase of 15.50.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
• For PBDIT Margin (%), as of Mar 25, the value is 3.93. This value is below the healthy minimum of 10. It has increased from 2.34 (Mar 24) to 3.93, marking an increase of 1.59.
• For PBIT Margin (%), as of Mar 25, the value is 3.62. This value is below the healthy minimum of 10. It has increased from 1.95 (Mar 24) to 3.62, marking an increase of 1.67.
• For PBT Margin (%), as of Mar 25, the value is 3.09. This value is below the healthy minimum of 10. It has increased from 1.22 (Mar 24) to 3.09, marking an increase of 1.87.
• For Net Profit Margin (%), as of Mar 25, the value is 2.28. This value is below the healthy minimum of 5. It has increased from 0.93 (Mar 24) to 2.28, marking an increase of 1.35.
• For Return on Networth / Equity (%), as of Mar 25, the value is 27.79. This value is within the healthy range. It has increased from 12.54 (Mar 24) to 27.79, marking an increase of 15.25.
• For Return on Capital Employeed (%), as of Mar 25, the value is 41.06. This value is within the healthy range. It has increased from 23.61 (Mar 24) to 41.06, marking an increase of 17.45.
• For Return On Assets (%), as of Mar 25, the value is 13.68. This value is within the healthy range. It has increased from 5.12 (Mar 24) to 13.68, marking an increase of 8.56.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.74. This value is within the healthy range. It has decreased from 1.02 (Mar 24) to 0.74, marking a decrease of 0.28.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 6.39. It has increased from 5.45 (Mar 24) to 6.39, marking an increase of 0.94.
• For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 24) to 1.45, marking an increase of 0.24.
• For Quick Ratio (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has increased from 0.61 (Mar 24) to 0.83, marking an increase of 0.22.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 19.53. This value exceeds the healthy maximum of 8. It has increased from 16.08 (Mar 24) to 19.53, marking an increase of 3.45.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 7.32. This value is within the healthy range. It has increased from 3.21 (Mar 24) to 7.32, marking an increase of 4.11.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.26. This value is within the healthy range. It has increased from 2.28 (Mar 24) to 5.26, marking an increase of 2.98.
• For Enterprise Value (Cr.), as of Mar 25, the value is 141.53. It has increased from 108.01 (Mar 24) to 141.53, marking an increase of 33.52.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.33, marking an increase of 0.01.
• For EV / EBITDA (X), as of Mar 25, the value is 8.52. This value is within the healthy range. It has decreased from 13.69 (Mar 24) to 8.52, marking a decrease of 5.17.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 24) to 0.27, marking an increase of 0.03.
• For Price / BV (X), as of Mar 25, the value is 3.36. This value exceeds the healthy maximum of 3. It has increased from 3.34 (Mar 24) to 3.36, marking an increase of 0.02.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 24) to 0.27, marking an increase of 0.03.
• For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness